» Articles » PMID: 23176378

Viremic Profiles in Asymptomatic and Symptomatic Chikungunya Fever: a Blood Transfusion Threat?

Overview
Journal Transfusion
Specialty Hematology
Date 2012 Nov 27
PMID 23176378
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The presence of a chikungunya virus (CHIKV) outbreak could have an impact on transfusion safety when there are a large number of infected persons during an epidemic. Serosurveys have found that 3% to 28% of infected persons remain asymptomatic and are potential disseminators of transfusion-associated chikungunya. However, the viremic profiles of asymptomatic chikungunya patients, the major determinant of the transfusion risk, are unknown.

Study Design And Methods: Data on CHIKV viremic profiles were obtained from a case-control study carried out in a chikungunya-affected area during the 2009 epidemic in Songkhla, Thailand. CHIKV-infected individuals were classified based on a combination of the patient's history and clinical and laboratory findings.

Results: There were 134 laboratory-proven CHIKV-infected cases, of whom 122 (91.0%) were symptomatic and 12 (9.0%) were asymptomatic. The viremic levels in the symptomatic infected individuals peaked on the first 3 days and lasted up to 8 days as defined by viral isolates. CHIKV genomic products were detected as late as Day 17 of illness. The viral loads observed in the symptomatic individuals (median, 5.6 × 10(5) plaque-forming units per milliliter [pfu/mL]; range, 1.3 × 10(1) -2.9 × 10(8) pfu/mL) were higher than but not significantly different from those observed in the viremic asymptomatic individuals (median, 3.4 × 10(3) pfu/mL; range, 8.4 × 10(1) -2.9 × 10(5) pfu/mL [p = 0.22, Wilcoxon test]).

Conclusion: CHIKV infection is highly symptomatic and is associated with high-titred viremia. The viremic levels in asymptomatic CHIKV-infected individuals were in the range known to be capable of transmitting the disease to experimental animals. Asymptomatic CHIKV viremia individuals could be potential disseminators of transfusion-associated chikungunya.

Citing Articles

Human migrations, anthropogenic changes, and insect-borne diseases in Latin America.

Wilke A, Farina P, Ajelli M, Canale A, Dantas-Torres F, Otranto D Parasit Vectors. 2025; 18(1):4.

PMID: 39789650 PMC: 11721252. DOI: 10.1186/s13071-024-06598-7.


Design and testing of Hepatitis Delta Ribozymes for suppression of Chikungunya virus infection in cell cultures.

Fraser M, Kucharski C, Loh Z, Hanahoe E, Fraser Jr M Med Res Arch. 2024; 12(8).

PMID: 39324067 PMC: 11423935. DOI: 10.18103/mra.v12i8.5762.


Cross-Neutralizing Anti-Chikungunya and Anti-Dengue 2 IgG Antibodies from Patients and BALB/c Mice against Dengue and Chikungunya Viruses.

Posadas-Mondragon A, Santiago-Cruz J, Perez-Juarez A, Herrera-Gonzalez N, Sosa-Delgado S, Wong-Arambula C Viruses. 2024; 16(7).

PMID: 39066260 PMC: 11281444. DOI: 10.3390/v16071098.


Development of Vaccines against Emerging Mosquito-Vectored Arbovirus Infections.

Principi N, Esposito S Vaccines (Basel). 2024; 12(1).

PMID: 38250900 PMC: 10818606. DOI: 10.3390/vaccines12010087.


Serological and Molecular Epidemiology of Chikungunya Virus Infection in Vietnam, 2017-2019.

Nguyen T, Ngwe Tun M, Cao M, Dao H, Luong C, Huynh T Viruses. 2023; 15(10).

PMID: 37896842 PMC: 10611313. DOI: 10.3390/v15102065.